UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 252

Sortiert nach

Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back

AIDS (London), 2019-12, Vol.33 (15), p.2387-2391

2019

Volltextzugriff (PDF)

Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry

Alimentary pharmacology & therapeutics, 2019-04, Vol.49 (8), p.1052-1059

2019

Volltextzugriff (PDF)

Editorial: Tenofovir disoproxil fumarate, more than an antiviral drug—Another piece of the puzzle

Alimentary pharmacology & therapeutics, 2024-01, Vol.59 (2), p.287-288

Mauss, Stefan

2024

Volltextzugriff (PDF)

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Journal of hepatology, 2019-05, Vol.70 (5), p.1019-1023

2019

Volltextzugriff (PDF)

Risk factors for mortality and clinical presentation of monkeypox

AIDS (London), 2023-11, Vol.37 (13), p.1979

2023

Volltextzugriff (PDF)

Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis

PloS one, 2022-05, Vol.17 (5), p.e0267853-e0267853

2022

Volltextzugriff (PDF)

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+ T Regulatory Cells Correlates with Progressive Disease

Journal of Virology, 2011-02, Vol.85 (3), p.1287-1297

2011

Volltextzugriff (PDF)

Risk factors for HCV transmission in HIV-positive men who have sex with men in México

PloS one, 2022-07, Vol.17 (7), p.e0269977-e0269977

2022

Volltextzugriff (PDF)

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

PloS one, 2022-06, Vol.17 (6), p.e0264741-e0264741

2022

Volltextzugriff (PDF)

Effect of antiviral therapy for HCV on lipid levels

Antiviral therapy, 2017, Vol.21 (1), p.81-88

2017

Volltextzugriff (PDF)

Late presentation of chronic viral hepatitis for medical care: a consensus definition

BMC medicine, 2017-05, Vol.15 (1), p.92-92, Article 92

2017

Volltextzugriff (PDF)

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study

PloS one, 2021-05, Vol.16 (5), p.e0250833-e0250833

2021

Volltextzugriff (PDF)

Real‐world effectiveness of sofosbuvir‐based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO‐03)

Journal of medical virology, 2018-02, Vol.90 (2), p.304-312

2018

Volltextzugriff (PDF)

Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis

PloS one, 2013-07, Vol.8 (7), p.e68152-e68152

2013

Volltextzugriff (PDF)

Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021

Frontiers in public health, 2023-05, Vol.11, p.1149694-1149694

2023

Volltextzugriff (PDF)

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

World journal of gastroenterology : WJG, 2014-08, Vol.20 (31), p.10984-10993

2014

Volltextzugriff (PDF)

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3

PloS one, 2014-09, Vol.9 (9), p.e107592-e107592

2014

Volltextzugriff (PDF)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy

PloS one, 2016-06, Vol.11 (6), p.e0156731-e0156731

2016

Volltextzugriff (PDF)

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Biomedicines, 2021-10, Vol.9 (10), p.1495

2021

Volltextzugriff (PDF)

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection

PloS one, 2012-08, Vol.7 (8), p.e43143-e43143

2012

Volltextzugriff (PDF)

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study

PloS one, 2016-07, Vol.11 (7), p.e0159976

2016

Volltextzugriff (PDF)

Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020-02, Vol.26 (2), p.205-210

2020

Volltextzugriff (PDF)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Hepatology communications, 2022-09, Vol.6 (9), p.2488-2495

2022

Volltextzugriff (PDF)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy

PloS one, 2015-04, Vol.10 (4), p.e0125080-e0125080

2015

Volltextzugriff (PDF)

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)

Substance abuse : research and treatment, 2019, Vol.13, p.1178221819835847

2019

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(228)

Publikationsform

Sprache

Englisch
(240)
Deutsch
(17)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Life Sciences & Biomedicine
(139)
Humans
(133)
Male
(89)
Infectious Diseases
(83)
Female
(79)
Adult
(77)
Middle Aged
(70)
Antiviral Agents - Therapeutic Use
(61)
Hepatitis C
(53)
Gastroenterology & Hepatology
(51)
Hiv
(49)
Human Immunodeficiency Virus
(49)
Hepatitis C, Chronic - Drug Therapy
(46)
Biological And Medical Sciences
(45)
Hepatitis
(44)
Medical Sciences
(42)
Hiv Infections - Drug Therapy
(40)
Viral Diseases
(38)
Aged
(37)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back

Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry

Editorial: Tenofovir disoproxil fumarate, more than an antiviral drug—Another piece of the puzzle

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Risk factors for mortality and clinical presentation of monkeypox

Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+ T Regulatory Cells Correlates with Progressive Disease

Risk factors for HCV transmission in HIV-positive men who have sex with men in México

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

Effect of antiviral therapy for HCV on lipid levels

Late presentation of chronic viral hepatitis for medical care: a consensus definition

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study

Real‐world effectiveness of sofosbuvir‐based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO‐03)

Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis

Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study

Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)

Suchergebnisse filtern